Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Immunotherapy and Other Nontargeted Approaches for Lung Cancer

Dr. Matthew Gubens, a clinical investigator from UCSF specializing in immunotherapy, discusses pivotal 2023 breakthroughs in treating non-small cell lung cancer (NSCLC) without actionable mutations. He highlights the evolution of immunotherapy, addressing challenges like colitis linked to genetic risk. Gubens also explores the impact of circulating tumor DNA on treatment choices and patient advocacy in complex cases. The conversation covers the potential of new therapies, including bispecific antibodies and antibody-drug conjugates, reshaping lung cancer treatment.